Yee Hoo Looi,
PhD
Council of Regulators
Health Sciences Authority Singapore Liaison to the DIA Board
Deputy Director, Therapeutic Products Branch, Health Sciences Authority Singapore
Dr. Yee Hoo Looi is the Deputy Director of Therapeutic Products Branch of the Health Products Regulation Group, Health Sciences Authority (HSA), which administers the regulation and pre-market evaluation for drug registration in Singapore. Dr. Looi started his career in HSA in 2009 as an evaluator for both clinical and toxicology review. He currently leads non-clinical evaluation and is also involved in overseeing the overall benefit-risk assessment for marketing approval.
Dr. Looi graduated with an Honours degree in Pharmacy and obtained a PhD in Pharmacology from the University of Strathclyde, United Kingdom in 2003. He completed his post-doctoral training at King’s College London, focusing on heart failure research. Prior to joining HSA, he was a pharmacologist at a pharmaceutical company, conducting safety assessment of drug candidates.
Our Leadership
-
Joseph Scheeren,
PharmD •Chair DIA
Senior Advisor R&D
Bayer AG -
John A. Roberts,
MBA •Immediate Past Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
Rebecca Vermeulen,
RPh •Chair-Elect DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd. -
Jeffrey S. Payne,
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
Barbara Lopez Kunz,
MS • Global Chief Executive
DIA
-
Andrzej Czarnecki,
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
Angelika Joos,
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
Judith Ng-Cashin,
MD •Director DIA
Chief Scientific Officer
Syneos Health -
Michael Romano,
CPA •Director DIA
Partner, Life Science Industry Practice Group, RSM US -
Michael Rosenblatt,
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
Jonathan Sheldon,
PhD •Director DIA
Senior Vice President
QIAGEN -
Kihito Takahashi,
MD, PhD •Director DIA
Vice President and Senior Managing Director, Development & Medical Affairs, GlaxoSmithKline Japan -
Lingshi Tan,
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
Cynthia L. Verst,
PharmD •Director DIA
President, R&D Design and Delivery Innovation, IQVIA
-
Joseph Scheeren,
PharmD • Chair, Executive Committee
-
Jeffrey S. Payne,
CPA • Member, Executive Committee -
John A. Roberts,
MBA • Member, Executive Committee -
Rebecca Vermeulen,
RPh • Member, Executive Committee -
Barbara Lopez Kunz,
MS • Member, Executive Committee
-
Michael Romano,
CPA • Chair, Audit Committee -
Andrzej Czarnecki,
MD, PhD, DSc • Member, Audit Committee -
Angelika Joos,
MPharm • Member, Audit Committee -
Joseph Scheeren,
PharmD • Member, Audit Committee -
Cynthia L. Verst,
PharmD • Member, Audit Committee
-
Yoshiaki Uyama,
PhD • Chair, Council of Regulators
Leadership Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board -
Peter Bachmann,
PhD • Council of Regulators
Leadership Committee
European Medicines Agency Liaison to the DIA Board -
Gerald J. Dal Pan,
MD • Council of Regulators
Leadership Committee
US Food and Drug Administration Liaison to the DIA Board -
Petra Dörr,
PhD • Council of Regulators
Swissmedic Liaison to the DIA Board
-
Barbara Lopez Kunz,
MS • Global Chief Executive -
Bayard G. Gardineer,
MS, CPA • Chief Financial Officer -
Timothy Hess • Global Director of IT
-
Thomas Bols • Senior Vice President & Managing Director
DIA EMEA -
Youngshin Lee,
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
Sudip S. Parikh,
PhD • Senior Vice President & Managing Director
DIA Americas -
Akio Uemura,
PhD • Senior Vice President & Managing Director
DIA Japan -
Carol Zhu,
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China